NewsBenzingaMorgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20 Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20 Benzinga 2026.09.18 16:30 (GMT+0) Open on Benzinga Other news 3M CEO Says Expanded Beam Optics Sales Could Likely Double Next Year Strive Closes Upsized $630M IPO Of 15% Series A Perpetual SATS Preferred Stock At $90/Share; Shares Expected To Begin Trading On Nasdaq Global Market Around October 20, 2026, Under Ticker 'SATS' RBC Capital Maintains Outperform on argenx, Lowers Price Target to $1025 Piper Sandler Maintains Overweight on Axon Enterprise, Lowers Price Target to $561 Genuine Parts Q3 2026 Earnings Call Transcript Barclays Maintains Equal-Weight on Werner Enterprises, Lowers Price Target to $38
Strive Closes Upsized $630M IPO Of 15% Series A Perpetual SATS Preferred Stock At $90/Share; Shares Expected To Begin Trading On Nasdaq Global Market Around October 20, 2026, Under Ticker 'SATS'
